Established in 2003, we are a leading Israeli Investment Company specializing in the Biotechnology sector and focusing exclusively on highly select opportunities in the life sciences including, therapeutics, diagnostic and agro-bio space. Coronis companies have demonstrated through superior management and financial planning- high growth, good financial stability and the ability to meet their development plans and goals. Since 2004, Coronis has invested over $10M in seven high quality portfolio companies. In 2007, four of our companies issued public offerings – BiondVax (TASE: BNDX) and Evogene (TASE: EVGN) in Tel Aviv; Rosetta Genomics (Nasdaq:ROSG) and Modigene (Nasdaq:MODG) at Nasdaq. Coronis performed partial exits in three of the four traded companies, with return on the initial price per share ranging between 5 to 6 fold in each of them (Evogene - Invested at $1 and Exited at $5; BiondVax - Invested at $0.45 and Exited at $2.26; Prolor - Invested at $1.5 and Exited at $8.6). The fifth company – Glycominds – has successfully completed a public offering in TASE in February 2011 (TASE: GLCM).
View Top Employees from Coronis Partners Ltd.Website | http://www.coronis-partners.com |
Revenue | $811000 |
Employees | 1 (0 on RocketReach) |
Founded | 2003 |
Address | Lev Hanevet Bldg, Ness Ziona, Central District, IL |
Phone | +972 8-936-3600 |
Technologies | |
Industry | Investment Management, Manufacturing General, Manufacturing |
SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 52 Companies, NAICS Code 32 Companies, NAICS Code 523 Companies, NAICS Code 325 Companies |
Looking for a particular Coronis Partners Ltd. employee's phone or email?
The Coronis Partners Ltd. annual revenue was $811000 in 2024.
Coronis Partners Ltd. is based in Ness Ziona, Central District.
The NAICS codes for Coronis Partners Ltd. are [52, 32, 523, 325].
The SIC codes for Coronis Partners Ltd. are [28, 283, 80].